HSBC has cut the target price on Biocon Ltd. from Rs 400 to Rs 390, as it sees negative impact on earnings per share due to the company's Rs 4,500-crore qualified institutional placement that ...

In a filing to the stock exchange, Biocon stated, "The U.S. Food and Drug Administration (USFDA) concluded a GMP inspection of our API facility (Site 6), located at Visakhapatnam, Andhra Pradesh ...

Shares of Biocon tumbled over 2 percent on June 18 after the US Food and Drug Administration issued three observations for its Active Pharmaceutical Ingredients (API) facility in Visakhapatnam.

Biocon: The US Food and Drug Administration (USFDA) concluded a GMP inspection of the company's API facility (Site 5), located at Visakhapatnam, Andhra Pradesh, on June 21, 2024, the company said ...

Biocon and Eris have expanded a previous agreement, with Biocon selling Indian branded formulations businesses to Mumbai-based Eris for $150M.

The biosimilars business accounted for 58% of Biocon's overall revenue in FY25. Biocon Biologics had said it would likely list itself on the exchanges by March 2026. However, after its January ...

Biocon gets 4 observations from USFDA for Andhra Pradesh facility The US Food and Drug Administration (USFDA) concluded a GMP inspection of the company's API facility (Site 5), located at ...